Kelun-Biotech Unveils Promising Phase 3 Results for Trastuzumab Botidotin at ESMO 2025 At the 2025 ESMO Congress, Kelun-Biotech revealed compelling Phase 3 trial results for Trastuzumab Botidotin, outperforming T-DM1 in HER2-positive breast cancer.

Kelun-Biotech Unveils Promising Phase 3 Results for Trastuzumab Botidotin at ESMO 2025 #China #Chengdu #Kelun-Biotech #ESMO_2025 #Trastuzumab_Botidotin

Lilly to Unveil Promising Clinical Findings for Verzenio and New Pipeline Developments at ESMO 2025 At the upcoming ESMO 2025, Lilly will showcase new clinical findings for Verzenio and various innovations in cancer treatment. Learn more about these promising advancements.

Lilly to Unveil Promising Clinical Findings for Verzenio and New Pipeline Developments at ESMO 2025 #Germany #Berlin #Verzenio #Lilly #ESMO_2025

Lupin to Present Phase I Data on LNP3693 at ESMO 2025 Congress Lupin Limited will showcase critical Phase I trial data for LNP3693, a STING agonist, at the ESMO 2025 Congress in Berlin, highlighting its potential in oncology.

Lupin to Present Phase I Data on LNP3693 at ESMO 2025 Congress #India #Mumbai #Lupin_Limited #ESMO_2025 #LNP3693

Astellas to Showcase Innovative Cancer Treatments at ESMO 2025 Astellas Pharma plans to unveil ten significant oncology abstracts at ESMO 2025, highlighting advancements in treatments that could transform patient outcomes.

Astellas to Showcase Innovative Cancer Treatments at ESMO 2025 #Japan #oncology #Tokyo #Astellas_Pharma #ESMO_2025

VolitionRx to Showcase Innovative Cancer Detection Strategies at ESMO 2025 VolitionRx will present groundbreaking research on cancer diagnostics at ESMO 2025, enhancing cancer detection and treatment decisions.

VolitionRx to Showcase Innovative Cancer Detection Strategies at ESMO 2025 #Paris #France #VolitionRx #ESMO_2025 #Cancer_Biomarkers